/
ORIC
$10.16+$0.63 (+6.56%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$986.5M
104M shares
52-week range
$7.23 – $14.93
38% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-7.54
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $900.0K | $1.0M | $0 | $0 | $0 | $1.0M | $1.1M | $1.2M |
| Gross profit | −$900.0K | −$1.0M | $0 | $0 | $0 | −$1.0M | −$1.1M | −$1.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $19.0M | $22.8M | $60.8M | $56.9M | $61.7M | $85.2M | $114.1M | $109.8M |
| Operating income | −$22.4M | −$28.6M | −$74.2M | −$78.9M | −$91.8M | −$110.8M | −$142.9M | −$143.0M |
| EBITDA | −$20.5M | −$25.9M | −$48.4M | −$77.8M | −$85.8M | −$99.7M | −$126.7M | −$128.2M |
| Net income | −$21.4M | −$26.9M | −$73.7M | −$78.7M | −$89.1M | −$100.7M | −$127.8M | −$129.5M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -12.32 | -1.40 | -3.36 | -2.07 | -2.25 | -1.96 | -1.83 | -1.47 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $8M | $-1.46 | $-1.58–$-1.35 | 12 |
| 2027 | $2M | $-1.59 | $-1.81–$-1.39 | 10 |
| 2028 | $9M | $-1.66 | $-1.86–$-1.35 | 7 |
| 2029 | $64M | $-1.76 | $-1.76–$-1.76 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.35
Price
$10.15
Implied downside
-97%
Peer comparison
Oric Pharmaceuticals, Inc. Common Stock
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
www.oricpharma.com- Employees
- 104
- IPO / List date
- Apr 24, 2020
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds ORIC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 572,724 | $4.7M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ORIC yet.
